2.40
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biosino Bio-Technology and Science
Its shares trade on HKEX under the ticker 8247.HK. It has been listed since 27 February 2006. In the fiscal year to 31 December 2025, it reported revenue of CN¥184.3m and a net loss of CN¥51.1m. At that date it held total assets of CN¥407.1m and shareholders' equity of CN¥120.2m.
Biosino Bio-Technology & Science, Inc. engages in the manufacture, sale, and distribution of in-vitro diagnostic reagents and pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2006-02-27. The Company’s products include mono diagnostic reagent products and double diagnostic reagent products. Its products categories include liver diseases category, kidney diseases category, lipid diseases category, cardiovascular diseases category, glycometabolism category, inorganic ion category, pancreas diseases category and specific protein category. Its products are sold to hospitals and medical institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Feb 2006
- Employees
- 531
- Website
- zhongsheng.com.cn ↗
Leadership
Pay as last reported
- Mr. Lebin WuExecutive Chairman of the Board, since 2020CN¥1.2m
- Mr. Peng ChenPresident, Executive Director, since 2021
- Mr. Zhengyong ChenExecutive Vice Chairman of the Board, since 2023
- Mr. Peng YangNon-Executive Vice Chairman of the Board
- Mr. Jianzhong LiuFinance Director, since 2018
- Ms. Xi CaoVice President
- Mr. Wanchen ZhangVice President
- Mr. King Yin ChengQualified Accountant
- Mr. Woon Cheung TungCompany Secretary
- Mr. Guangxia GaoNon-Executive Director
- Mr. Zhonghua LiNon-Executive Director
- Dr. Xin HeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biosino's 531 employees support diverse product categories including liver and kidney disease diagnostics.
- The company's in-vitro diagnostic reagents are sold to hospitals and medical institutions nationwide.
- Biosino's product portfolio covers cardiovascular and glycometabolism disease categories.
Weaknesses
- Biosino's IPO in 2006 may indicate limited recent market expansion opportunities.
- The company's focus on diagnostic reagents might restrict diversification into new markets.
- Biosino's reliance on hospitals for sales could create dependency on a single customer segment.
Opportunities
- Expanding into lipid disease diagnostic products could capture new market segments.
- Growth in cardiovascular disease diagnostics aligns with global health trends.
- Increasing demand for glycometabolism tests presents a significant market opportunity.
Threats
- Competition from other biotechnology firms in the Health Care sector may intensify.
- Regulatory changes in China's diagnostic reagent market could impact operations.
- Economic downturns might reduce hospital spending on diagnostic products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.